Prostaglandin E2/EP favors IBD-CRC development by switching the phenotype of macrophages and neutrophils to pro-tumor, increasing cellular migration through the up-regulation of vascular endothelial growth factor receptor-1 signaling and by activating NF-κB. This evidence concerns the gene NFKB1 and inflammatory bowel disease.